Abstract
Regardless of having a similar antihypertensive effect, different antihypertensive drug classes have a different effect on albuminuria. Patients with albuminuria will usually need more than one drug to achieve blood pressure control, particularly if the aim is also to reduce albuminuria. Albuminuria is independently associated with cardiovascular and renal risk regardless of diabetes status. The recent ESC/ESH guidelines listed microalbuminuria among the hypertension-mediated organ damages. Albumin-to-creatinine ratio was suggested to be included in routine workup for evaluation of every hypertensive patient and changes in albuminuria were considered to have moderate prognostic value. Because of its specific effects on renal hemodynamic and glomerular structure, the ACEIs and ARBs should be prescribed in maximum tolerated doses. The MRAs can be considered in uncontrolled hypertensive patients. The CCBs can be used in addition to the RAAS blockade. Data on antialbuminuric effect of the new CCBs generation (T-type and N-type calcium channel blockers) is promising and they might be preferential CCBs when available. In case of resistant hypertension, thiazide or thiazide-like diuretic has to be added into the combination with RAAS blockers and other antihypertensive drugs. Low-salt intake has to be recommended for all hypertensive patients, particularly those with albuminuria. A multifactorial and early antialbuminuric approach should be started even when albuminuria values are below the cut-off value for microalbuminuria.
Keywords: Arterial hypertension, microalbuminuria, proteinuria, cardiovascular disease, target organ damage, RAAS-inhibition, angiotensin converting enzyme inhibitors, calcium channel blockers, angiotensin ii receptor blockers, Mineralocorticoid receptor antagonist, thiazide-like diuretic.
Current Pharmaceutical Design
Title:Treatment of Hypertension Induced Albuminuria
Volume: 24 Issue: 37
Author(s): Tamara Knežević, Lana Gellineo, Ana Jelaković, Vedran Premužić, Živka Dika, Mario Laganović and Bojan Jelaković*
Affiliation:
- Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Croatia School of Medicine, University of Zagreb, Zagreb,Croatia
Keywords: Arterial hypertension, microalbuminuria, proteinuria, cardiovascular disease, target organ damage, RAAS-inhibition, angiotensin converting enzyme inhibitors, calcium channel blockers, angiotensin ii receptor blockers, Mineralocorticoid receptor antagonist, thiazide-like diuretic.
Abstract: Regardless of having a similar antihypertensive effect, different antihypertensive drug classes have a different effect on albuminuria. Patients with albuminuria will usually need more than one drug to achieve blood pressure control, particularly if the aim is also to reduce albuminuria. Albuminuria is independently associated with cardiovascular and renal risk regardless of diabetes status. The recent ESC/ESH guidelines listed microalbuminuria among the hypertension-mediated organ damages. Albumin-to-creatinine ratio was suggested to be included in routine workup for evaluation of every hypertensive patient and changes in albuminuria were considered to have moderate prognostic value. Because of its specific effects on renal hemodynamic and glomerular structure, the ACEIs and ARBs should be prescribed in maximum tolerated doses. The MRAs can be considered in uncontrolled hypertensive patients. The CCBs can be used in addition to the RAAS blockade. Data on antialbuminuric effect of the new CCBs generation (T-type and N-type calcium channel blockers) is promising and they might be preferential CCBs when available. In case of resistant hypertension, thiazide or thiazide-like diuretic has to be added into the combination with RAAS blockers and other antihypertensive drugs. Low-salt intake has to be recommended for all hypertensive patients, particularly those with albuminuria. A multifactorial and early antialbuminuric approach should be started even when albuminuria values are below the cut-off value for microalbuminuria.
Export Options
About this article
Cite this article as:
Knežević Tamara , Gellineo Lana , Jelaković Ana , Premužić Vedran , Dika Živka , Laganović Mario and Jelaković Bojan *, Treatment of Hypertension Induced Albuminuria, Current Pharmaceutical Design 2018; 24 (37) . https://dx.doi.org/10.2174/1381612825666181126170354
DOI https://dx.doi.org/10.2174/1381612825666181126170354 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke
Current Pharmaceutical Design Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Evaluation of the Effect of Nimodipine o.d. (Extended Release) vs Nimodipine t.i.d. in the Treatment of Peripheral Vertigo
Current Drug Delivery Cu-Based Solid Catalysts: Applications in Organic Transformations for NHeterocyclic Compounds
Current Organic Chemistry Preface [Hot topic: Modern Aspects in the Design And Discovery of Novel Antihypertensive Drugs (Guest Editor: Thomas Mavromoustakos)]
Current Topics in Medicinal Chemistry Chronic Kidney Disease and the Risk of Cardiovascular Disease Events: A Community-Based Approach
Vascular Disease Prevention (Discontinued) Update on Drug Interactions With Phosphodiesterase-5 Inhibitors Prescribed as First-Line Therapy for Patients with Erectile Dysfunction or Pulmonary Hypertension
Current Drug Metabolism Imidazoline Receptors and their Ligands as Potentiators of Nutrient-Induced Insulin Secretion
Drug Design Reviews - Online (Discontinued) Potential Therapeutics for Vascular Cognitive Impairment and Dementia
Current Neuropharmacology Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews The Pathobiology of Endothelin-1 in Vein Graft Disease: Are ETA Receptor Antagonists the Solution to Prevent Vein Graft Failure?
Current Vascular Pharmacology Pathogenesis and Therapeutics of Interstitial Lung Disease in Systemic Sclerosis
Current Rheumatology Reviews Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology Editorial (Hot Topic: Autosomal Dominant Polycystic Kidney Disease: Cardiovascular Complications)
Current Hypertension Reviews Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry Alerting Reaction in Office Blood Pressure and Target Organ Damage: An Innocent Phenomenon?
Current Hypertension Reviews Sleep in Pediatric Pulmonary Diseases
Current Respiratory Medicine Reviews Neural Mechanisms of Exercise: Effects on Gut Miccrobiota and Depression
CNS & Neurological Disorders - Drug Targets The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design